Priming of cancer cells with low dose naltrexone
AssigneeLDN Pharma Limited
InventorsAngus Dalgleish, Wai Liu
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods of treating a tumor/cancer by administering naltrexone or an analogue thereof, followed by a recovery phase, and then administering a small molecule signaling inhibitor such as PI3-kinase inhibitors, AKT inhibitors, taxanes, antimetabolites, alkylating agents and/or cell cycle inhibitors. The disclosure also provides diagnostic methods for assessing a therapeutic response to the methods of treatment.
Claims13
A method of treating a subject having a tumor/cancer selected from the group consisting of lung cancer, colorectal carcinoma, glioma and pancreatic cancer comprising administering to the subject in a first treatment phase naltrexone at a dose between 0.01 mg/kg and 0.08 mg/kg, followed by a recovery phase;
- wherein, following the recovery phase, a small molecule signaling inhibitor selected from the group consisting of PI3-kinase inhibitors, AKT inhibitors, taxanes, antimetabolites, alkylating agents and cell cycle inhibitors is administered to the subject in a second treatment phase;
- the recovery phase being characterized by the absence of administration of the naltrexone and the small molecule signaling inhibitor and wherein said recovery phase is for at least 1 day.
Dependencies are inferred from the claim text.